Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
GRCV MARIJUANA FARMS and other news:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110328879
WHAT IS THE NEXT FLUFF PR IN CEO'S HAT
MAY BE BUYING APPLE TO GET THEIR IPHONE BUINESS LOL LOL
JMHO
BUY NOW or regret later. GRCV is UNDERVALUED!
People are BUYING GRCV.
GRCV will pop and will fly into multiple penny land.
BUY NOW or regret later!
GRCV is UNDERVALUED!
Go GRCV ********************
Please read this all the way to the bottom Marijuana Stocks 2015: What You Need to Know
By Todd Campbell | More Articles
January 20, 2015 | Comments (2)
Both medical and recreational marijuana have been in the news over the past year, with changes in both social acceptance and legal status in different parts of the country. Tune in to learn what investors should know when looking at marijuana-related stocks.
This health care edition of Industry Focus looks at what it actually means to invest in marijuana stocks in today's market, what investors should keep in mind, and how the two leading medical marijuana companies stack up.
Michael Douglass: Marijuana stocks in 2015. This is Industry Focus.
[INTRO]
Hi Fools, health care analyst Michael Douglass here today. The topic of the day is going to be marijuana stocks. I've got Todd Campbell on hangouts with us, from New Hampshire. Todd, how are you doing?
Todd Campbell: I'm doing really well. I remembered to wear my green shirt today.
Douglass: That's important. We actually didn't match this time, which is a shame. We do about half the time. I guess my people will call your people. We'll make sure that happens more in the future, all right?
All right, sounds good. One of the things that biotech investors, health care investors -- heck, general retail investors -- are really interested in is marijuana stocks, particularly because we've got some marijuana stocks with some incoming catalysts in 2015 and 2016. We wanted to spend a little bit of time talking about them and looking at their opportunities, and what we think about them as stocks.
Let's start with the granddaddy in the field which is, I think we have to say, GW Pharma (NASDAQ: GWPH ) . They are the name that is always on the tip of somebody's tongue when we're talking about cannabidiol or marijuana stocks. Todd, what's your take?
Campbell: Marijuana stocks caught a lot of attention last year. I think part of that was because of the election cycle. There were some pretty key elections that were going on, that were addressing both expanding medical marijuana, and also there was some recreational marijuana legislation that was being voted on last fall as well.
Overall in the marijuana space, as you mention GW Pharma is one of only two that I would define as being investable marijuana stocks. By "investable" I mean that they're widely traded on major exchanges.
Anybody who watched "The Wolf on Wall Street" knows that you should probably avoid pink sheet stocks.
Douglass: Yes!
Campbell: That's where a lot of these marijuana stocks outside of GW Pharma and Insys Therapeutics (NASDAQ: INSY ) tend to trade. We tend to focus here on more widely traded stocks. They're more proven than some of these others.
Last year you had GW Pharma and Insys, both of them returned about 64% on the year, a really big showing for those two companies. That excitement centered mainly around both of the companies' work on basically taking the chemical compounds that are found in marijuana, synthesizing those, and then delivering those to patients to try and help indications that really have an unmet need.
For example, GW Pharma has been studying its drug Sativex for use in cancer pain. It's also been studying CBD for use in epilepsy. In 2015, GW Pharma is going to roll out more data that investors will be able to dissect and digest, to see whether or not they want to be long the stock heading into the 2016 election year cycle.
Personally, I'm not a huge fan of GW Pharma for 2015 because I think that the stock run last year may have made it a little bit pricy.
Douglass: Yes, I think that's a fair concern. Traditional valuation is a little tough in health care because earnings per share, as shown by a number of stocks, those can quadruple one year on another.
But when you look at their price to sales, for example, for the trailing 12 months, it's 33 according to Yahoo! Finance. That is a pretty substantial ... that's priced to perfection, and I think that there are a couple of concerns there.
For me, one of the big ones is there's an election that says, "We're legalizing marijuana in X state," and immediately the so-called marijuana stocks get affected, even though these are really going through the FDA. It's a biotech cannabidiol. It's not really what you traditionally think of as marijuana, A.
Then B, there's also this recent Sativex Phase III trial in cancer pain, in which Sativex -- a GW drug -- basically failed to beat placebo. Now of course, this is the first of three Phase III trials there, but I think it's a little bit of a concern for investors who have just priced this stock so high.
Campbell: Michael, that's an awesome point because what it does is it really points to what it is that an investor is trying to accomplish with buying marijuana stocks. I think that a lot of people are looking at it and saying, "Look what happened to people who invested in alcohol after prohibition ended," or "Look at how big the market is for tobacco products. Could marijuana be that big someday?"
Unfortunately, right now there's no real companies that you can invest in, in the stock market, that are handling the legal cannabis side of things.
Douglass: Right.
Campbell: GW Pharma and Insys, to your point, they're researching synthetic drugs that are based on the chemical components of marijuana. Those are going to have to go through FDA trials, prove themselves through those trials, and get approved.
In the case of Sativex, they were unable to beat placebo in the first of the three Phase III trials that are going to give us data readouts this year. That's not a ringing endorsement.
What it does is it reminds me of what happened 10-15 years ago with tobacco. There was a lot of interest in developing treatments or medicine based on tobacco, that ended up going nowhere because when push came to shove, clinical trials couldn't show the efficacy could outperform anything else.
Douglass: Right. When it comes down to any biotech stock data is key, and so far in this particular indication Sativex data hasn't been good. Now of course, could it have good data in this indication in these other Phase III trials? Could it have good data in other indications? Of course.
But when you have a stock that's priced this richly, I think you have to have perfect execution, just about, to justify that valuation. I think that's a very legitimate concern for Foolish, relatively risk-averse investors to have.
Now, let's turn the conversation over to Insys. This is a stock you're a little bit more bullish on than GW Pharma. What's your elevator pitch for it?
Campbell: Insys is an intriguing company. It's more intriguing to me than GW Pharma because it's already generating revenue. It already has a product on the market. It markets a drug called Subsys. Subsys is an opiate spray that's used to treat breakthrough cancer pain, and it's been a really big success.
Sales of the drug doubled in the most recently reported quarter, the third quarter, to about $58 million. It's a drug that's already doing about $230-240 million a year. Insys has the same market cap as GW Pharma, that doesn't have any revenue aside from Sativex is approved for MS spasticity in Europe, and maybe they get $5-6 million a year in sales from that.
I think Insys has proven itself. It has revenue that's giving it financial flexibility. That financial flexibility means that it's debt-free, there's less chance of dilution, and it has plenty of money that it can reinvest into its own marijuana research programs, which are studying CBD also for epilepsy.
Many GW Pharma investors would argue that epilepsy is the reason to own GW Pharma. I would say that Insys has the same opportunity, but it has better financials.
Douglass: Yes, and when you look at that revenue differential -- again, just quoting Yahoo! Finance -- GW Pharma's is under $50 million for the trailing 12 months, and Insys' is right around $200 million, so you have the same valuation on 4x the sales. Okay, that may be a better opportunity for folks.
You can see that difference in that price to sales ratio -- it's only 8, for instance -- which I know is still rich by most valuations, but in biotech it's not really that far off the beaten path.
Campbell: Yes. For full disclosure, I happen to long Insys, so I want to make sure that people are aware of that.
Douglass: Sure.
Campbell: One of the other things that I think investors need to be watching for in Insys is that the early stage research for epilepsy drugs is intriguing, but they have a much closer catalyst in their oral new formulation of the long-standing marijuana drug Marinol, which of course has been used for 20-some odd years to help reduce chemotherapy-induced nausea.
They have what they think is a better mousetrap for that marijuana drug. It's a $150 million market that's growing 4% a year. They think they can capture a lot of that market if they can win FDA approval.
They've had some hiccups as far as their filing of information with the FDA, but supposedly that's going to get filed this quarter, which could clear the way for an approval and have it go on market sometime early in '16.
Douglass: Sure. I'll say again, looking at it from a valuation perspective and from a potential growth perspective, Insys is not -- me personally -- my style of investing. But again, one of the nice things about The Motley Fool, we're motley!
We definitely have differing viewpoints on companies, and we believe that an open and free marketplace of ideas about them is going to make us all better investors, so I think it's really important for us to have disagreements.
For me, when I look at that market size and the potential growth, it looks too rich for me. I still worry about the association with marijuana bump, getting people unreasonably excited, catalysts that have nothing to do with the business -- like marijuana legalization in a certain state bumping the stock for no reason.
That's the sort of thing that always concerns me, and it's a worry for me going forward for the business. But I will say, if you're really interested in the space and you're putting your money somewhere, I would definitely prefer Insys to GW. I like their opportunities better.
Campbell: Yes, I think you make a great point as far as, investors generally speaking have not done well chasing fads or whatever's in the news for the moment.
You need to approach these things not through rose-colored lenses, but you need to do your homework, your due diligence, and you need to be willing to admit when you're wrong, especially when it comes to investing in biotechnology companies.
The reality is that 90% of drugs fail in clinical trials, so the odds are kind of stacked against you in that regard. You need to be willing to say, "I'm willing, after doing my homework, to take on the risk of being completely wrong."
Douglass: Yes, that is part of the deal. Certainly one thing we're all about here at The Motley Fool is educating people and making sure that they have the data they need to make smart decisions.
Todd, thank you for your thoughts on marijuana stocks today. I think this has been a really good conversation, and one that I think is going to be ongoing since we always seem to talk about them a little bit, on- and off-camera!
Let's definitely circle back up on this, especially once data is out from our friends at the J.P. Morgan conference this afternoon on Insys. That will be very interesting. Until then folks, stay tuned to Fool.com and the Industry Focus podcast for all of your investing needs, and Fool on!
Todd Campbell has no position in any stocks mentioned. The Motley Fool owns shares of JPMorgan Chase. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
The Next Industry To Crumble...
Imagine owning Amazon.com (up over an insane 4,000% since 2001) when Internet sales rendered big-box retailers obsolete...
Or Apple (up over a mindboggling 6,000% since 2004) when smartphones made landlines irrelevant.
Now an industry 99% of us use daily is set to implode... And 3 established companies are perfectly positioned to take advantage of this game-changing economic shift. That's why I urge you to click below to find out which industry is going the way of the dinosaur... and how YOU can take advantage.
Click to see the stunning presentation.
Read/Post Comments (2) | Recommend This Article (3)
Email Print Feedback 9
Email Print
Comments from our Foolish Readers
Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.
Report this Comment On January 28, 2015, at 11:21 PM, SELLmtg wrote:
GRCV is in the FINAL stages of negotiations with a MARIJUANA FARM in Bend, Oregon (Source: otcmarkets.com, type in GRCV, Click on "News", Read the 1/8/15 news).
GRCV=0.0002 and will go up higher. GRCV is a strong buy.
Report this Comment On January 28, 2015, at 11:41 PM, SHEEPSKAPE wrote:
TRTC is a unmitigated disaster. Massive pending Dilution through toxic financing.
-167
$HEEP
Add your comment.
Your Fool username will be displayed with your comment.
Please be respectful with your comments. Review our Fool's Rules.
Your comment may be delayed up to 15 minutes
Compare Brokers
E*TRADE
Open Account
TD Ameritrade
Open Account
Sharebuilder
Open Account
Fidelity
Open Account
Fool Disclosure
Sponsored Links
Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!
I was about to say the same thing. 50 million shares snapped up @.0002. I hope this is the beginning of something big.
GRCV MARIJUANA FARM, MARIJUANA FARM.
GRCV is in the FINAL stages of negotiations with a MARIJUANA FARM located in Bend, Oregon.
http://www.otcmarkets.com/otciq/ajax/showNewsReleaseDocumentById.pdf?id=13069
Information about the MARIJUANA FARM in Bend, Oregon.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110233384
Oregon is the RIGHT state for GRCV because Oregon has legalized MARIJUANA for RECREATIONAL uses in Nov 2014.
GRCV is UNDERVALUED.
GRCV is a strong buy, imo.
Go GRCV ******************************
I see many OTC releases
Otcexchange then some mj stuff then software acquisition ???
What does this co do actually other then selling shares???
Jmho
Question to the board.
Why this co puts out news in OTC not any wire. Isnt it a big deal with otcexchange.info site and what it can provide. If genuine why not let the investment community know in ä big way.
Is this a scam ??
Jmho
Unusual increase in buying today. Does anyone know something?
All speculation on what they are doing and cause of the selloff. What's important now is L2 see if we can break through main resistance .0003 then things will start to improve.
agree lukin4winners
For a company that wants to promote company transparency.
they would do well explaining what happened on the Dec23rd sell off.
The fact that it's not addressed concerns me.
Then they keep adding projects (mms farm and trading software)
from other directions before getting the primary task up and going.
What I don't like on the mmj farm is no income details, and not real details.
what I don't like about the trading software is that it sounds like they picked it up at a bankruptcy auction.
That may be good, it may be great...I don't know.
GRCV .0002 falling once .0003 breaks we have a big move coming off the bottom imo. Way oversold here.
The reason some trade GRCV and companies like this is the tremendous upside potential. If GRCV was trading in pennies the risk would be a lot higher than .0003. Don't forget it was .0065 before someone or multiple persons decided to sell preferred or some other form of shares for reasons that havn't been fully disclosed. Be that as it may the upside here is looking much better at .0003 than .0065 and it was just over .01 not that long ago.
Every time someone sees the otcexchange.info in google they see words like halted, suspended and more.
Yes, I know it's about the problem companies in their news but maybe it scares GRCV investors away who don't look further.
Is posting lousy companies really a benefit? I would rather know about great companies that are doing something. that have credible management, new patents and things like that.
First PR in a long time shows that the ceo has been diligently working on bringing a new direction to GRCV since the catastrophic selloff which was out of his control. Looking forward to additional pr's on progress.
http://www.otcmarkets.com/otciq/ajax/showNewsReleaseDocumentById.pdf?id=13069
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110233384
The above is a GOOD MARIJUANA FARM NEWS!
Go GRCV *******************
Once the news is digested and the chart is viewed traders will see the potential here from before the drop off @.0065 which was one day and looks like someone inside needed some cash. More than likely a preferred share holder.
http://stockcharts.com/h-sc/ui?s=GRCV&p=D&yr=0&mn=6&dy=0&id=p53263158262
Great post! Thanks for the great NEWS!
The market looks forward, NOT backward!
Forward looking people catch the next wave and make a fortune.
GRCV will pop and will fly into multiple penny land!
Go GRCV **********************
Correnti still hasn't mentioned the Dilutionfest - just putting out fluff to sell shares, wonder how many he handed out to the fake note holders this month.
GRCV IS UNDERVALUED, GRCV IS UNDERVALUED:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110262061
Go GRCV $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
0003s please!!! :)) Let's go only 50 mil on ask!!!
Powerful news! Looks like Mr Correnti resolved the issues which led to the insider selloff of preferred big move coming here. Risk/reward in our favor.
http://stockcharts.com/h-sc/ui?s=GRCV&p=D&yr=0&mn=6&dy=0&id=p38360369148
Thanks! GOOD NEWS! GOOD NEWS! GOOD NEWS!
http://www.otcmarkets.com/otciq/ajax/showNewsReleaseDocumentById.pdf?id=13309
http://www.currensys.com/
With the above, I believe that GRCV is READY to launch its OTCEXCHANGE.info in Q1 2015.
MARIJUANA NEWS:
GRCV is in the FINAL stages of negotiations with a MARIJUANA grow farm in Bend, Oregon.
http://www.otcmarkets.com/otciq/ajax/showNewsReleaseDocumentById.pdf?id=13069
Information about the MARIJUANA FARM in Bend, Oregon:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110233384
GRCV is UNDERVALUED. GRCV is a STRONG BUY, imo.
Go GRCV ***********************
JC can't figure what he wants this scam to be.
Its a replacement for OTCMarkets
Then a doper's paradise farm
and now its gonna be a super-trading software turd.
Where does Mikey find these clowns to be the face of his scams?
NEWS Grand Capital Ventures Announces Final Phases of Asset Purchase from Stock Market Trading Software Company
Sunrise, FL January 28, 2015 - Grand Capital Ventures (OTC PINK: GRCV) is pleased to announce that we are in the final stages of negotiations for an asset purchase from an algorithmic trading software company (www.currensys.com).
John Correnti, CEO of Grand Capital Ventures, says, “This company has been operating in this market since 2007 and has a strong existing customer base. The technical reviews and specifications of this new program are very advanced and will give our customer base a tool from which to make educated profitable trading decisions. The program generates buy and sell signals based on a proprietary code on the following markets, stocks, options, futures and forex.”
John Correnti, also states, "We believe that this will not only help our brokerage clients making wise buying and selling decisions it will help our overall brokerage revenue based on additional transactional revenues. We feel very strongly about the diversity that we are developing for our shareholders and www.currensys.com is another step in that direction”.
About Grand Capital Ventures, Inc.:
Grand Capital Ventures, Inc. specializes in working with underperforming companies and bringing together the resources needed for them to attain financial stability and growth. Our focus is on companies showing a positive upside while striving to bring new technologies and unique products to market.
Safe Harbor Statement:
This release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E and or 27E of the Securities Exchange Act of 1934 that are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including statements as to the future performance of the company and the risks and uncertainties detailed from time to time in reports filed by the company with the Securities and Exchange Commission. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements.
Investors are cautioned that forward-looking statements are inherently uncertain. Although the company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Factors that could cause results to differ include, but are not limited to, the company’s ability to raise necessary financing, retention of key personnel, timely delivery of inventory from the company’s contract manufacturers, timely product development, product acceptance, and the impact of competitive services and products, in addition to general economic risks and uncertainties. Grand Capital Ventures, Inc.: Mr. John P. Correnti, President/CEO john@grandcapitalventures.
GRCV great news first ticker that came up on their software was GRCV as a total POS, from .01 to .0003 in a day, lost my ass on this one stay the fuck away anyone with any brains
GRCV has BOTH marijuana farm (in the final stages of negotiations) and
OTCExchange(launch in Q1 2015).
Posting 5 times a day ? I believe that "should be MORE than 5 times ". GRCV is UNDERVALUED and I should let people know, I should get the words out.
Pumping ? NO, SIR! I am just telling the truth.
GRCV is a good stock with a great future. The below post also agrees with me.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=109026870
GRCV is the best investment and I believe that GRCV will pop and will fly into multiple penny land.
MARIJUANA legalization is REAL, is here to stay!
Go GRCV ****************************
News out on otcmarkets
http://www.otcmarkets.com/otciq/ajax/showNewsReleaseDocumentById.pdf?id=13309
Grand Capital Ventures Announces Final Phases of Asset Purchase from
Stock Market Trading Software Company
Sunrise, FL January 28, 2015 - Grand Capital Ventures (OTC PINK: GRCV) is pleased to
announce that we are in the final stages of negotiations for an asset purchase from an algorithmic
trading software company (www.currensys.com).
John Correnti, CEO of Grand Capital Ventures, says, “This company has been operating in this
market since 2007 and has a strong existing customer base. The technical reviews and
specifications of this new program are very advanced and will give our customer base a tool
from which to make educated profitable trading decisions. The program generates buy and sell
signals based on a proprietary code on the following markets, stocks, options, futures and forex.”
John Correnti, also states, "We believe that this will not only help our brokerage clients making
wise buying and selling decisions it will help our overall brokerage revenue based on additional
transactional revenues. We feel very strongly about the diversity that we are developing for our
shareholders and www.currensys.com is another step in that direction”.
legal, I'm long and strong and can't lose much at these levels but why are you incessantly pumping GRCV to no end. What real fact are you basing your theory on here? What proof of progress other than the same ol same ol "Bend OR, Madison Ave, going into multiple penny land and every thing you've been posting 5 times or more a day.
Please share with me what exactly has the company released that is real and concrete other than conjecture that GRCV will be different from other penny stocks that have gone by the way side. TIA & GL
HCIT
GRCV MARIJUANA FARM. GRCV MARIJUANA FARM:
GRCV is in the FINAL STAGES OF NEGOTIATIONS with a MARIJUANA GROW FARM in Bend, Oregon.
http://www.otcmarkets.com/otciq/ajax/showNewsReleaseDocumentById.pdf?id=13069
INFORMATION about the MARIJUANA GROW FARM in Bend, Oregon:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110233384
Oregon is the RIGHT state for GRCV because Oregon has legalized MARIJUANA for RECREATIONAL uses in Nov 2014.
GRCV has been making all the right moves into the multi billion dollar marijuana industry.
GRCV will pop and will fly into multiple penny land.
GRCV is a STRONG BUY, imo.
Go GRCV **********************************
FOR GRCV SS,PRICE TARGETS,COMPARISONS...Click here:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110262061
Go GRCV **********************
GLAD to ANSWER your post, SIR.
1)"HIS BS targets" ? 2)"Clown" ?
1)"HIS BS targets" ?
The GRCV price targets are determined by chart/technical analysis.
These price targets have nothing to do with GRCV's CEO. Also, GRCV's CEO DIDN'T (Repeat: DIDN'T) determine these price targets.
SCIENCE determines GRCV price targets(SCIENCE = Supports, Resistances, Volumes, MACD, RSI,...).
Science is THE AMERICAN WAY, SIR.
There is NO "HIS BS targets" as you stated!
2) "CLOWN" ?
Well! Well! Well!.......... Who is the CLOWN now ?
Go GRCV *******************************
I'm long and HOLDING GRCV!
Yeah that clown makes sht up on all the tripz tickers and eventually he gets one right when his sheeple buy into his BS targets with zero basis.
GRCV SS,PRICE TARGETS ***********************
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110219398
GRCV is a strong buy, imo.
Go GRCV ***********************
http://www.otcmarkets.com/otciq/ajax/showNewsReleaseDocumentById.pdf?id=13069
GRCV is in the FINAL STAGES of negotiations with a MARIJUANA grow FARM located in Bend, Oregon.
GRCV is a strong buy at this price, imo.
Go GRCV *********************************
***********GRCV is in a consolidation period****************
GRCV will pop and will fly into multiple penny land RIGHT AFTER this consolidation period.
Go GRCV *******************************
I noticed on the FINRA link that Perlstein is still the beneficial owner of MVP.
Also, I noted that MVP has a financial deficit of $21,000 which violates net capital requirements.
Not good so far.
So where is the exchange? In the box at the cross section of 33rd and Madison, where how many points against the driving record for blocking box? Or at some random campus in Texas?
Also, MVP shows its offices at a residence on Wall Street. Most of those Wall Street buildings have been converted to apartments now.
Yeah I'm wondering why it isn't showing up either. It went through with that 3 milly .0002 pop. Id averaged down to .00021, can't say I'm upset
I don't see any sales today, only buy orders executed at .0002. There aren't any at .0001, how did you sell them then - GLTU
HCIT
OUT! Praise Jesus.
Later yall, never again.
Followers
|
249
|
Posters
|
|
Posts (Today)
|
4
|
Posts (Total)
|
27490
|
Created
|
05/31/07
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |